Translational Vision Science & Technology

Translational Vision Science & Technology is published by Association for Research in Vision and Ophthalmology Inc. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Retinal Diseases and Treatments, Glaucoma and retinal disorders and Ophthalmology and Visual Impairment Studies, together about 40.3% of its articles. Its main subfields are Radiology, Nuclear Medicine and Imaging. (generated from OpenAlex topic counts and CAS ranking data)

The conceptualization of translational research has expanded since the inception of Translational Vision Science and Technology (TVST). The expanded scope of translational research necessitates that we likewise expand the scope of the journal. TVST will publish work that fits into phases T1 through T4 translational research. Some examples are as follows: T1: Development and validation of animal models, preclinical drug studies, development of clinically relevant technologies, and phase 1 and 2 clinical studies (“bench to bedside” research). T2: Phase 3 clinical trials (including comparative effectiveness trials), phase 4 clinical research, and development of clinical guidelines (“bedside to practice” research). T3: Research focused on implementation and dissemination of phase 3 and 4 clinical research results (dissemination and implementation research). T4: Research focused on outcomes and effectiveness in populations, including assessment of benefit to communities through public health policies and programs, as well as adoption of proven interventions’ best practices in communities (diffusion research), and cost-benefit analyses. This classification scheme is best conceived as a continuum, a natural progression of investigative activity, rather than as a series of clearly defined categories. As a result of the change in scope, the number and diversity of publications accepted by the journal is likely to increase compared with past years. ARVO's commitment to this expanded scope will enable TVST to better represent the diversity of research that is already represented in platform and poster presentations at the annual ARVO meeting. This scope change will enable ARVO to represent the interests of its members and to advance the development and assessment of treatments for blinding diseases worldwide. *For a more detailed description and discussion please see Marco Zarbin's editorial at TVST 2020;9(8):22. Short updates on new developments and controversies will be published by invitation. TVST encourages the use of color, multimedia, hyperlinks, program code and other digital enhancements. TVST will utilize and take advantage of every technological innovation afforded by digital data management to optimize TVST’s computer-based reading experience. Manuscripts from scientists and clinicians with diverse backgrounds ranging from basic chemistry to ophthalmic surgery, bringing together research that, until now, often has been published in journals other than tho

From the journal's Aims & Scope

Research area (LetPub): Engineering-Biomedical Engineering

Editor-in-chief Roy S. ChuckPublisher website

CAS Journal Ranking

Database indexing

SCIEScopusDOAJLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

2.72LetPub · 2026-09-13

CiteScore 2026-06

4.6LetPub · 2026-09-13

SJR 2026-06

0.94LetPub · 2026-09-13

SNIP 2026-06

1.05LetPub · 2026-09-13

h-index

12LetPub · 2026-09-13

h-index

72OpenAlex · 2026-10-01

i10-index

1,534OpenAlex · 2026-10-01

2-year mean citedness

3.08OpenAlex · 2026-10-01

Self-citation rate

7.4%LetPub · 2026-09-13

Share of gold OA articles

99.61%LetPub · 2026-09-13

Volume

Articles per year

377LetPub · 2026-09-13

Articles per year (publisher)

2,012Publisher website · 2026-10-01

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Average review time (community reports)

about 25 weeksLetPub · 2026-09-13

Submission to publication (journal-reported)

about 25 weeksDOAJ · 2026-10-25

Peer review

Unspecified peer reviewDOAJ

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

• APC information ↗DOAJ
• Fee waivers ↗DOAJ
• Open access statement ↗DOAJ
• License & copyright ↗DOAJ

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Association for Research in Vision and Ophthalmology Inc.

Country or region

UNITED STATES

Language

English

ISSN

2164-2591

Society / sponsor

Association for Research in Vision and Ophthalmology

Latest issue on the website

Volume 15, Issue 9 (September 2026)

Official links

• Journal homepage ↗DOAJ
• Submission system ↗LetPub
• Author guidelines ↗DOAJ
• Aims & Scope ↗DOAJ
• Special issues ↗Publisher website
• APC information ↗DOAJ
• Fee waivers ↗DOAJ
• Open access statement ↗DOAJ
• License & copyright ↗DOAJ
• Peer review process ↗DOAJ
• Editorial board ↗DOAJ
• Plagiarism policy ↗DOAJ